DLL3 and cancer: In a recent study, 63 patients with SCLC underwent immunohistochemistry (IHC) for DLL3: 52 patients (83%) were positive for DLL3 expression, with 20 patients (32%) showing high expression of DLL3 (positive in at least 50% of cancer cells) (17).